Founder and Managing Director of Arboretum Ventures in Ann Arbor. Garfinkle specializes in medical technology investments, using her educational background in biomedical engineering, extensive operating experience, and industry connections to select and nurture outstanding companies. Her investing activities focus primarily on FDA 510(k) and PMA medical device and diagnostics companies. Garfinkle serves on the board of directors for HandyLab, VasoNova, and Mirabilis Medica and as an observer for Uptake Medical and BAROnova. Prior to founding Arboretum in 2002, she spent 20 years in senior management positions in entrepreneurial healthcare companies. Garfinkle was founder and president of Strategic Marketing Consultants, a consulting firm focused on the commercialization of healthcare technologies for start-ups and large medical-device manufacturers. Earlier, she worked for two successful medical-device start-up companies, Advanced Cardiovascular Systems and Devices for Vascular Intervention, both of which were acquired by Eli Lilly and Co. for more than $100 million and became the foundation for Guidant Corp., which Eli Lilly later spun off in 1994. She joined each company early in its development and held key management roles in marketing, clinical research, and sales. Garfinkle began her career as a manufacturing engineer and production line manager for Proctor & Gamble. She has served on a number of advisory boards focused on capital formation and enhancing the commercialization of promising technologies. She is a board member and past president of the Michigan Venture Capital Association. Additionally, she is a member of the Commercialization Advisory Board of the Global Cardiovascular Innovation Center at the Cleveland Clinic. Garfinkle earned her bachelor’s degree in bioengineering from the University of California at Berkeley and her master’s degree from the Wharton School at the University of Pennsylvania.